Researchers developed a method for placing microscopic sensor particles within the printed material itself, allowing researchers to measure nutrient levels—and infer cell health from this information—using only light.
Researchers from the Atopy (Allergy) Research Center of the Juntendo University Graduate School of Medicine in Japan, led by Prof. François Niyonsaba, along with co-authors Quan Sun and Ge Peng, explored the relationship between melanoma cells and keratinocytes, the most abundant cells in the skin that surround melanoma cells.
Researchers have evaluated a novel smart wheeled walker designed to enhance mobility and safety for aging populations. Published in JMIR Aging, the randomized crossover trial revealed that the smart wheeled walker significantly improved walking speed, reduced exertion and boosted dynamic balance compared with a traditional 4-wheeled rollator.
When added to standard chemotherapy, a clinical version of the dietary supplement L-glutamine improved survival in an early-phase trial of patients with advanced pancreatic cancer. The study, led by Cedars-Sinai Health Sciences University investigators, was published in Nature Cancer.
Rice University and collaborators in Switzerland have developed a platform to grow human-derived nerve cells and Schwann cells, supporting cells that form a protective coating called myelin around nerve fibers.
Most current flu vaccines—especially those given by injection—do not reliably build strong immune memory in the airways, leaving a gap in protection against initial infection and transmission.
In their quest to understand how cancers take root, grow and spread, scientists have for the past half-century explored the genetic aberrations and microenvironmental peculiarities of tumors and their constituent cells.
Triple-negative breast cancer (TNBC) has a frustrating ability to adapt. Although this aggressive form of breast cancer can initially respond well to chemotherapy, cancer cells often find ways to survive, allowing the disease to return and become resistant to treatment.
The FDA granted the approval of Revolution Medicines’ daraxonrasib, now to be known as Rasonque, in pancreatic adenocarcinoma 6.5 months ahead of deadline.
Immunotherapies such as CAR T-cell therapy are used primarily to treat cancer. In the future, these patient-specific therapies, manufactured from patients’ own immune cells, could also help cure autoimmune diseases.